Editing CSL Limited (section)

=== Acquisition and merging of Novartis ===
In October 2014, [[Novartis]] announced its intention to sell its influenza vaccine business, including its development pipeline, to CSL for $275 million. CSL merged it into its BioCSL operation.<ref>{{cite web|first=Alex|last=Phillipidis|url=http://www.genengnews.com/gen-news-highlights/novartis-selling-flu-vaccine-business-to-csl-for-275m/81250520/|title=Novartis Selling Flu Vaccine Business to CSL for $275M|work=Genetic Engineering & Biotechnology News|date=27 October 2014|access-date=22 May 2020}}</ref>

In November 2015, BioCSL rebranded the combined business with Novartis Influenza Vaccines as ''Seqirus'' [Sek-eer-us], creating the world's second-largest influenza vaccine company.<ref>[http://www.csl.com.au/Seqirus.htm Sequirus] Commonwealth Serum Laboratories</ref>

In August 2017, the business announced it would acquire Calimmune and its stem cell therapy platform.<ref>{{cite press release |title=CSL Behring Acquires Biotech Company Calimmune and its Proprietary Stem Cell Gene Therapy Platform |url=https://investors.csl.com/site/PDF/f00cb92f-cb30-4ed5-a5db-40a2c960f233/CSLBehringAcquiresUSBiotechCompanyCalimmune |publisher=CSL  |date=2017-08-06 |access-date=2021-12-15}}</ref>

Completed in 2018, Seqirus's Holly Spring, NC, the plant was funded with $59 million from the U.S. government.<ref>{{cite news|last=Willman|first=David|url=https://www.washingtonpost.com/investigations/federal-vaccine-development-sites-ill-suited-to-counter-covid-19-epidemic/2020/03/15/34e8586c-63c4-11ea-acca-80c22bbee96f_story.html|title=Federal vaccine development sites ill-suited to counter covid-19 epidemic|newspaper=The Washington Post|date=15 March 2020|access-date=15 March 2020}}</ref>

in June 2020, CSL announced it would exercise its right to acquire Vitaeris.<ref>{{cite press release |title=CSL to Acquire Biotech Company Vitaeris |url=https://investors.csl.com/site/PDF/471311e9-12c0-4075-8f46-d595377b96d2/CSLtoAcquireBiotechCompanyVitaeris |publisher=CSL  |date=2020-09-06 |access-date=2021-12-15}}</ref>

In December 2021, the business announced it would acquire Swiss drugmaker, [[Vifor Pharma]] AG, for $11.7 billion.<ref>{{cite web|url=https://www.reuters.com/markets/europe/australias-csl-buy-swiss-drugmaker-vifor-117-billion-2021-12-13/|date=2021-12-14|access-date=2021-12-15|title=Australia's CSL to buy Swiss drugmaker Vifor for $11.7 bln|first1=Nikhil|last1=Nainan|first2=Silke|last2=Koltrowitz|first3=Scott|last3=Murdoch|work=Reuters}}</ref>

In August 2022, CSL rebranded all of its divisions to start with the CSL name. Therefore, the divisions became [[CSL Behring]], [[CSL Plasma]], [[CSL Seqirus]], and [[CSL Vifor]].<ref>{{Cite web |last=Coey |first=Sharon Klahr |date=2022-08-26 |title=CSL to unite all business units, including Seqirus, under the CSL umbrella |url=https://www.fiercepharma.com/marketing/csl-unite-all-business-unit-including-seqirus-under-one-csl-umbrella |url-status=live |archive-url=https://web.archive.org/web/20220826150412/https://www.fiercepharma.com/marketing/csl-unite-all-business-unit-including-seqirus-under-one-csl-umbrella |archive-date=2022-08-26 |website=Fierce Pharma}}</ref>